Effect of pioglitazone on the expression of renal tissue podocalyxin in STZ-induced diabetic rats
Yan XING,Shan-dong YE,Wen HU,Ke CHEN,Yu-mi CHEN,Yan CHEN,Ai-hong FAN
DOI: https://doi.org/10.3969/j.issn.1001-1978.2011.07.024
2011-01-01
Abstract:Aim: To investigate the reno-protective effect of different dosages of hydrochloride pioglitazone and its effect on the expression of glomerular podocalyxin(PCX) in STZ-induced diabetic rats. Methods: Diabetic models were established by a single injection of streptozotocin ( STZ 65 mg · kg -1). Diabetic rats were randomly divided into following four groups: diabetic rats without treatment (DM, diabetic model group, n =8) 10,20 and 30 mg · (kg · d)-1 pioglitazone (PIO) treated diabetic rats (group DR1, DR2 and DR3, n = 8 respectively). 8 healthy rats were served as a normal control group (group NC). Urinary albumin (UALB), urinary retinol-bindingprotein (URBP), urinary sediment PCX(UPCX) and urinary creatinine (UCr) were measured at 0 and the end of the 8th week. To eliminate the impact of urine volume, the parameters mentioned above were expressed as UACR, URCR, UPCR, respectively. At the end of the 8th week, HbA1c levels were assessed and the left kidney was microdissected for morphometric analysis. Renal tissue PCX mRNA and protein expression were determined by RT-PCR and immunohistochemistry respectively. Results: Circled digit one The blood glucose levels throughout the study period along with HbA1c at the end of the 8 th week in diabetic rats were significantly higher than those in group NC (P < 0.05), whereas no significant differences were found between PIO-treated groups and group DM. Circled digit twoAt the end of the 8th week, the levels of UACR, URCR, KI, glomerular basement membrane thickness (GBMT) and foot process fusion ratio (FPFR) decreased significantly in PIO-treated groups compared with group DM, while the variables mentioned above in group DR2 and DR3 groups were lower than those of DR1 group. In addition, the levels of UPCR in group DR2 and DR3 decreased when compared with group DM (P < 0.05), whereas UPCR in group DR1 was slightly lower than that of DM group (P >0.05). Down-regulation of the mRNA and protein expression of PCX was inhibited by PIO-therapy, the levels of PCX protein both in group DR2 and DR3 were higher than that of DR1 group (P < 0.05). Circled digit three At the end of the 8th week, the parameters including SCr, BUN, TG, LDL-C were significantly higher, whereas serum HDL-C was lower compared with those of group NC. Pioglitazone therapy markedly decreased the level of BUN and TG(P <0.05). Notably, HDL-C in group DR2 and DR3 were higher than group DR1 ( P < 0.05). Circled digit four UPCR was positively correlated with UACR and KI respectively (r = 0.868, r = 0.833, P < 0.01). Conclusion: Pioglitazone can alleviate kidney injury of diabetic rats, which may be to some extent related to its functions in restraining the loss of PCX in the urine and inhibiting the down-regulation of the mRNA and protein expression of podocyte PCX in a dose-dependent mode.